Loading...

David B. Agus, MD

Title(s)Professor of Medicine and Biomedical Engineering
AddressWMB 9033 Wilshire Blvd
Health Sciences Campus
Beverly Hills CA 90211
Phone+1 310 272 7640
vCardDownload vCard
    Other Positions
    Title(s)Director, Lawrence J. Ellison Institute for Transformative Medicine of USC

    Title(s)Director, USC Center for Applied Molecular Medicine


    Collapse Biography 
    Collapse Awards and Honors
    American Cancer Society1996  - 2001Physician Research Award
    Sloan-Kettering Institute1996Clinical Scholar Award
    American Cancer Society1994Clinical Oncology Fellowship Award
    HealthNetwork Foundation2008Excellence Award
    Geoffrey Beene Foundation2009Rock Stars of Science™
    Biotech Humanitarian Award2009Selected Judge
    USC Association of Trojan Leagues2013Outstanding Service Award
    American College of Physicians2016Fellow
    Ellis Island Medal of Honor2017Medalist

    Collapse Overview 
    Collapse Overview
    Dr. David B. Agus is a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and the founding director of USC’s Lawrence J. Ellison Institute for Transformative Medicine.   Dr. Agus leads a multidisciplinary team of researchers dedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs, and directs a National Cancer Institute Physical Sciences in Oncology Center at USC.  He is a medical oncologist and the co-founder of several personalized medicine companies. Dr. Agus is an international leader in new technologies and approaches for personalized healthcare, serving in leadership roles at the World Economic Forum, among other prestigious organizations. Dr. Agus’ first book called “The End of Illness” was published in 2012 and is a New York Times #1 and international best seller and was the subject of a PBS series, and his most recent books “A Short Guide to a Long Life” and “The Lucky Years: How to Thrive in the Brave New World of Health” are also New York Times and international bestsellers. Dr. Agus graduated cum laude with honors in molecular biology from Princeton University, and received his medical degree from the University of Pennsylvania School of Medicine. He completed his medical internship and residency training at Johns Hopkins Hospital.

    Collapse Research 
    Collapse Research Activities and Funding
    (PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
    NIH/NCI R01CA180149Sep 5, 2013 - Jul 31, 2017
    Role: Principal Investigator
    UCLA SPORE in Prostate Cancer
    NIH/NCI P50CA092131Jul 1, 2001 - Jun 30, 2013
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Faculty Mentoring
    Collapse Twitter
    Collapse Featured Videos
    Collapse Required Scholarly Project Mentor

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Deep learned tissue "fingerprints" classify breast cancers by ER/PR/Her2 status from H&E images. Sci Rep. 2020 Apr 29; 10(1):7275. Rawat RR, Ortega I, Roy P, Sha F, Shibata D, Ruderman D, Agus DB. PMID: 32350370.
      View in: PubMed   Mentions:    Fields:    
    2. Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2020 Mar 03. Gross ME, Agus DB, Dorff TB, Pinski JK, Quinn DI, Castellanos O, Gilmore P, Shih JC. PMID: 32123315.
      View in: PubMed   Mentions:    Fields:    
    3. Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA). BMC Res Notes. 2019 May 15; 12(1):275. Patsch K, Matasci N, Soundararajan A, Diaz P, Agus DB, Ruderman D, Gross ME. PMID: 31092276.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City. Addict Behav. 2019 06; 93:14-19. Truong C, Krawczyk N, Dejman M, Marshall-Shah S, Tormohlen K, Agus D, Bass J. PMID: 30682677.
      View in: PubMed   Mentions:    Fields:    
    5. Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens. NPJ Breast Cancer. 2018; 4:32. Rawat RR, Ruderman D, Macklin P, Rimm DL, Agus DB. PMID: 30211313.
      View in: PubMed   Mentions:
    6. Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol. 2017 11; 18(11):e653-e706. Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A. PMID: 29208398.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    7. Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clin Genitourin Cancer. 2017 Jul 14. Gross ME, Dorff TB, Quinn DI, Diaz PM, Castellanos OO, Agus DB. PMID: 28826933.
      View in: PubMed   Mentions: 1     Fields:    
    8. JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. Mol Cancer Ther. 2017 08; 16(8):1645-1657. Kani K, Garri C, Tiemann K, Malihi PD, Punj V, Nguyen AL, Lee J, Hughes LD, Alvarez RM, Wood DM, Joo AY, Katz JE, Agus DB, Mallick P. PMID: 28566434.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    9. Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial. Am Heart J. 2017 Jul; 189:94-102. Fröbert O, Götberg M, Angerås O, Jonasson L, Erlinge D, Engstrøm T, Persson J, Jensen SE, Omerovic E, James SK, Lagerqvist B, Nilsson J, Kåregren A, Moer R, Yang C, Agus DB, Erglis A, Jensen LO, Jakobsen L, Christiansen EH, Pernow J. PMID: 28625387.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    10. The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older. PLoS One. 2016; 11(11):e0166103. Agus DB, Gaudette É, Goldman DP, Messali A. PMID: 27902693.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    11. Single cell dynamic phenotyping. Sci Rep. 2016 10 06; 6:34785. Patsch K, Chiu CL, Engeln M, Agus DB, Mallick P, Mumenthaler SM, Ruderman D. PMID: 27708391.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    12. Quantifying differences in cell line population dynamics using CellPD. BMC Syst Biol. 2016 Sep 21; 10(1):92. Juarez EF, Lau R, Friedman SH, Ghaffarizadeh A, Jonckheere E, Agus DB, Mumenthaler SM, Macklin P. PMID: 27655224.
      View in: PubMed   Mentions: 2     Fields:    
    13. A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Sci Rep. 2016 07 25; 6:29752. Garvey CM, Spiller E, Lindsay D, Chiang CT, Choi NC, Agus DB, Mallick P, Foo J, Mumenthaler SM. PMID: 27452732.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    14. A Plasma-Based Protein Marker Panel for Colorectal Cancer Detection Identified by Multiplex Targeted Mass Spectrometry. Clin Colorectal Cancer. 2016 06; 15(2):186-194.e13. Jones JJ, Wilcox BE, Benz RW, Babbar N, Boragine G, Burrell T, Christie EB, Croner LJ, Cun P, Dillon R, Kairs SN, Kao A, Preston R, Schreckengaust SR, Skor H, Smith WF, You J, Hillis WD, Agus DB, Blume JE. PMID: 27237338.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    15. Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS). Sci Rep. 2016 Mar 03; 6:22435. Chiu CL, Patsch K, Cutrale F, Soundararajan A, Agus DB, Fraser SE, Ruderman D. PMID: 26936218.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    16. Stochasticity and determinism in cancer creation and progression. Converg Sci Phys Oncol. 2015 Dec; 1(2). Davies PC, Agus DB. PMID: 29170717.
      View in: PubMed   Mentions:
    17. THE DOCTOR WILL SEE YOU (AND YOUR DATA) NOW. Fortune. 2016 Jan 01; 173(1):90-3. Agus DB. PMID: 26875351.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19-31. Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. PMID: 26244007.
      View in: PubMed   Mentions:
    19. Aligning incentives to fulfil the promise of personalised medicine. Lancet. 2015 May 23; 385(9982):2118-9. Dzau VJ, Ginsburg GS, Van Nuys K, Agus D, Goldman D. PMID: 25957453.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    20. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015 Mar 01; 33(7):723-31. Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R. PMID: 25624429.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    21. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Invest New Drugs. 2015 Apr; 33(2):397-408. Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G. PMID: 25556680.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    22. Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. Psychooncology. 2015 Feb; 24(2):228-35. Eisenberg SA, Kurita K, Taylor-Ford M, Agus DB, Gross ME, Meyerowitz BE. PMID: 24891013.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    23. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44. Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus DB. PMID: 24418642.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    24. The Value of Diagnostic Testing in Personalized Medicine. Forum Health Econ Policy. 2013 Sep 01; 16(2):S87-S99. Goldman DP, Gupta C, Vasudeva E, Trakas K, Riley R, Lakdawalla D, Agus D, Sood N, Jena AB, Philipson TJ. PMID: 31419871.
      View in: PubMed   Mentions:    Fields:    
    25. A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 2013; 3:1449. Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V, O'Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH. PMID: 23618955.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    26. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Apr; 31(2):409-16. Gordon MS, Mendelson DS, Gross M, Uttenreuther-Fischer M, Ould-Kaci M, Zhao Y, Stopfer P, Agus DB. PMID: 23242861.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    27. Perspective: Meeting of minds. Nature. 2012 Nov 22; 491(7425):S61. Agus DB, Gell-Mann M. PMID: 23320291.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Reframe the health debate. Fortune. 2012 Oct 29; 166(7):22. Agus DB. PMID: 23156666.
      View in: PubMed   Mentions:    Fields:    Translation:PHPublic Health
    29. A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol. 2012 Oct; 30(10):918-20. Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, Gatto L, Fischer B, Pratt B, Egertson J, Hoff K, Kessner D, Tasman N, Shulman N, Frewen B, Baker TA, Brusniak MY, Paulse C, Creasy D, Flashner L, Kani K, Moulding C, Seymour SL, Nuwaysir LM, Lefebvre B, Kuhlmann F, Roark J, Rainer P, Detlev S, Hemenway T, Huhmer A, Langridge J, Connolly B, Chadick T, Holly K, Eckels J, Deutsch EW, Moritz RL, Katz JE, Agus DB, MacCoss M, Tabb DL, Mallick P. PMID: 23051804.
      View in: PubMed   Mentions: 352     Fields:    Translation:Humans
    30. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013 Feb 15; 73(3):306-15. Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus DB, Mallick P, Gross ME. PMID: 22911164.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    31. Body image predicts quality of life in men with prostate cancer. Psychooncology. 2013 Apr; 22(4):756-61. Taylor-Ford M, Meyerowitz BE, D'Orazio LM, Christie KM, Gross ME, Agus DB. PMID: 22422671.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    32. Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. Mol Cancer Ther. 2012 May; 11(5):1071-81. Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB, Mallick P. PMID: 22411897.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    33. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 05; 8(6):2069-79. Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F. PMID: 21995722.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    34. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemother Pharmacol. 2012 Jan; 69(1):273-80. Gross ME, Leichman L, Lowe ES, Swaisland A, Agus DB. PMID: 22002543.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    35. Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma. PLoS One. 2011; 6(7):e23090. Fang Q, Kani K, Faca VM, Zhang W, Zhang Q, Jain A, Hanash S, Agus DB, McIntosh MW, Mallick P. PMID: 21829587.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    36. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 2011 Jan; 21(1):47-55. Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S, Beckstrom-Sternberg J, Barrett M, Long J, Chinnaiyan A, Lowey J, Suh E, Pearson JV, Craig DW, Agus DB, Pienta KJ, Carpten JD. PMID: 21147910.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    37. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs. 2012 Apr; 30(2):749-57. Alva A, Slovin S, Daignault S, Carducci M, Dipaola R, Pienta K, Agus D, Cooney K, Chen A, Smith DC, Hussain M. PMID: 21049281.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCellsCTClinical Trials
    38. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling. Prostate. 2010 Aug; 70(11):1201-10. Mink SR, Hodge A, Agus DB, Jain A, Gross ME. PMID: 20564426.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    39. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010 Sep; 56(9):1492-5. Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME. PMID: 20581083.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    40. Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol Cancer Res. 2010 Jun; 8(6):809-20. Mink SR, Vashistha S, Zhang W, Hodge A, Agus DB, Jain A. PMID: 20530582.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    41. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res. 2010 Mar 01; 70(5):1989-99. Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K, Tindell C, Agus DB. PMID: 20160029.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    42. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009 Oct; 8(10):2882-93. Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, Agus DB, Jain A. PMID: 19825806.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    43. Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping. Psychooncology. 2009 May; 18(5):508-14. Christie KM, Meyerowitz BE, Giedzinska-Simons A, Gross M, Agus DB. PMID: 18756584.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    44. Multiparameter computational modeling of tumor invasion. Cancer Res. 2009 May 15; 69(10):4493-501. Bearer EL, Lowengrub JS, Frieboes HB, Chuang YL, Jin F, Wise SM, Ferrari M, Agus DB, Cristini V. PMID: 19366801.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    45. Precursor-ion mass re-estimation improves peptide identification on hybrid instruments. J Proteome Res. 2008 Sep; 7(9):4031-9. Luethy R, Kessner DE, Katz JE, Maclean B, Grothe R, Kani K, Faça V, Pitteri S, Hanash S, Agus DB, Mallick P. PMID: 18707148.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    46. ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics. 2008 Nov 01; 24(21):2534-6. Kessner D, Chambers M, Burke R, Agus D, Mallick P. PMID: 18606607.
      View in: PubMed   Mentions: 425     Fields:    
    47. Personalized genetics: a responsible approach. Am J Hum Genet. 2008 Jul; 83(1):130; author reply 131. Stephan D, Agus D, Nierenberg M, Silver E. PMID: 18606304.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. The current state of preclinical prostate cancer animal models. Prostate. 2008 May 01; 68(6):629-39. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL. PMID: 18213636.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    49. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer. 2007 Jul 27; 7:142. Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB. PMID: 17662137.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    50. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res. 2007 Apr 01; 13(7):1979-86. Gross M, Top I, Laux I, Katz J, Curran J, Tindell C, Agus D. PMID: 17404077.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    51. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007 Feb 20; 25(6):675-81. Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI. PMID: 17308272.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    52. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1208-15. Dreicer R, Petrylak D, Agus D, Webb I, Roth B. PMID: 17317831.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    53. Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery. Clin Adv Hematol Oncol. 2006 Jul; 4(7):541-9. deVera IE, Katz JE, Agus DB. PMID: 17147241.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    54. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int. 2006 Apr; 97(4):691-7. Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus DB. PMID: 16536755.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCTClinical Trials
    55. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer. 2006 Jan 16; 94(1):85-92. Laux I, Jain A, Singh S, Agus DB. PMID: 16306877.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    56. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer. 2005 Dec 15; 104(12):2701-8. Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, Agus DB, Koeffler HP. PMID: 16265675.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    57. A perspective on protein profiling of blood. BJU Int. 2005 Sep; 96(4):477-82. Katz JE, Mallick P, Agus DB. PMID: 16104895.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    58. Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci U S A. 2005 Aug 16; 102(33):11858-63. Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A, Afar DE, Aronson N, Shak S, Natale RB, Agus DB. PMID: 16087880.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimals
    59. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005 Apr 10; 23(11):2534-43. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. PMID: 15699478.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansCTClinical Trials
    60. PPARgamma signaling: one size fits all? Cell Cycle. 2004 Nov; 3(11):1352-4. Jain A, Agus DB. PMID: 15467471.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    61. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate. 2004 Nov 01; 61(3):228-35. Galkin AV, Mullen L, Fox WD, Brown J, Duncan D, Moreno O, Madison EL, Agus DB. PMID: 15368474.
      View in: PubMed   Mentions: 27     Fields:    Translation:AnimalsCells
    62. Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell. 2004 Jun; 5(6):565-74. Hedvat M, Jain A, Carson DA, Leoni LM, Huang G, Holden S, Lu D, Corr M, Fox W, Agus DB. PMID: 15193259.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    63. Ductal adenocarcinoma of the prostate. Clin Adv Hematol Oncol. 2004 Jun; 2(6):393-5; discussion 396. Shazer RL, Luthringer D, Agus DB, Gross ME. PMID: 16163211.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    64. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 01; 22(3):537-56. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. PMID: 14752077.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    65. Targeting the HER-kinase axis in cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 3):9-20. Gross ME, Shazer RL, Agus DB. PMID: 15052539.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    66. Update on HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol Oncol. 2004 Jan; 2(1):53-6, 64. Gross ME, Jo S, Agus DB. PMID: 16163160.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    67. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003 Jul 15; 63(14):4196-203. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL. PMID: 12874026.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimals
    68. Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. J Natl Cancer Inst. 2002 Nov 06; 94(21):1641-7. Bonham MJ, Galkin A, Montgomery B, Stahl WL, Agus D, Nelson PS. PMID: 12419791.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    69. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res. 2002 Oct; 8(10):3226-31. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, Agus DB. PMID: 12374693.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimals
    70. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002 Aug; 2(2):127-37. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX. PMID: 12204533.
      View in: PubMed   Mentions: 247     Fields:    Translation:HumansAnimalsCells
    71. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene. 2002 Jul 18; 21(31):4739-46. Gery S, Sawyers CL, Agus DB, Said JW, Koeffler HP. PMID: 12101412.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    72. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 2002 May 15; 99(10):3748-55. Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA. PMID: 11986232.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    73. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002 May; 8(5):986-93. Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N. PMID: 12006510.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansAnimalsCells
    74. Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. Proc Natl Acad Sci U S A. 2001 Sep 25; 98(20):11720-4. Huang J, Agus DB, Winfree CJ, Kiss S, Mack WJ, McTaggart RA, Choudhri TF, Kim LJ, Mocco J, Pinsky DJ, Fox WD, Israel RJ, Boyd TA, Golde DW, Connolly ES. PMID: 11573006.
      View in: PubMed   Mentions: 50     Fields:    Translation:Animals
    75. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res. 2001 Sep; 7(9):2643-7. Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, Ross JS, Cordon-Cardo C. PMID: 11555574.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    76. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. J Immunother (1991). 2001 May; 24(3):272-279. Treon SP, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC. PMID: 11395644.
      View in: PubMed   Mentions: 11     Fields:    
    77. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res. 2001 Apr; 7(4):962-70. Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA. PMID: 11309347.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    78. A potential role for activated HER-2 in prostate cancer. Semin Oncol. 2000 Dec; 27(6 Suppl 11):76-83; discussion 92-100. Agus DB, Akita RW, Fox WD, Lofgren JA, Higgins B, Maiese K, Scher HI, Sliwkowski MX. PMID: 11236032.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    79. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100. Agus DB, Bunn PA, Franklin W, Garcia M, Ozols RF. PMID: 11236029.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimals
    80. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res. 2000 Nov 01; 60(21):6134-41. Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM. PMID: 11085537.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    81. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000 Sep 15; 60(18):5165-70. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM. PMID: 11016644.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansAnimalsCells
    82. Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res. 2000 May 01; 60(9):2317-22. McDonald S, Brive L, Agus DB, Scher HI, Ely KR. PMID: 10811100.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    83. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999 Dec; 17(12):3776-85. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD. PMID: 10577849.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCellsCTClinical Trials
    84. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999 Nov 03; 91(21):1869-76. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI. PMID: 10547394.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansAnimals
    85. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. 1999 Oct 01; 59(19):4761-4. Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW. PMID: 10519379.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    86. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res. 1999 Sep 15; 59(18):4555-8. Agus DB, Vera JC, Golde DW. PMID: 10493506.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    87. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res. 1998 Jul 15; 58(14):3009-14. Agus DB, Golde DW, Sgouros G, Ballangrud A, Cordon-Cardo C, Scher HI. PMID: 9679964.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimals
    88. Workgroup 2: human xenograft models of prostate cancer. Prostate. 1998 Jun 15; 36(1):56-8. Stearns ME, Ware JL, Agus DB, Chang CJ, Fidler IJ, Fife RS, Goode R, Holmes E, Kinch MS, Peehl DM, Pretlow TG, Thalmann GN. PMID: 9650917.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    89. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest. 1997 Dec 01; 100(11):2842-8. Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, Vera JC, Golde DW. PMID: 9389750.
      View in: PubMed   Mentions: 63     Fields:    Translation:AnimalsCells
    David's Networks
    Concepts (434)
    Derived automatically from this person's publications.
    _
    Co-Authors (36)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _